Trogarzo™ (ibalizumab-uiyk)
Effective 06/01/19

Plan
☒ MassHealth
☒ Commercial/Exchange

Benefit
☐ Pharmacy Benefit
☒ Medical Benefit (NLX)

Program Type
☒ Prior Authorization
☐ Quantity Limit
☐ Step Therapy

Specialty Limitations
N/A

Overview
Trogarzo (ibalizumab-uiyk) is a CD4-directed post-attachment HIV-1 inhibitor, in combination with other antiretroviral(s), is indicated for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen.

Coverage Guidelines
Trogarzo may be approved if the member meets all the following criteria and documentation has been submitted:
- Member is diagnosed with HIV-1 infection
- Member is 18 years of age or older
- Prescriber is an infectious disease or HIV specialist experienced in the use of this treatment
- Documentation that the member has exhausted oral and injectable treatments available for HIV and requires Trogarzo to achieve effective antiretroviral combination therapy, optimized with at least 1 and preferably 2 fully active agents with demonstrated full viral sensitivity /susceptibility
- Member is currently using other antiretrovirals
- Documentation of resistance to at least one antiretroviral medication from each of these antiretroviral medication classes (including combination agents):
  - NRTI (Combivir, Viread, Epivir, etc.)
  - NNRTI (Edurant, Intelence, Sustiva, etc.)
  - PI (Prezista, Evotaz, Aptivus, etc.)
- Recent HIV ribonucleic acid viral load (within last 8 weeks) of > 200 copies/mL persisting after at least 6 months of antiretroviral therapy.

Limitations
1. Initial approvals will be for 6 months.
2. Reauthorizations will be for 12 months

References

Review History
02/20/2019 – Reviewed

Disclaimer
AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.